Join

Compare · NBY vs NVO

NBY vs NVO

Side-by-side comparison of NovaBay Pharmaceuticals Inc. (NBY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NBY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $187.53B, about 14343.9x NBY ($13.1M).
  • Over the past year, NBY is down 33.8% and NVO is down 41.7% - NBY leads by 7.9 points.
  • NVO has hit the wire 11 times in the past 4 weeks while NBY has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 0 for NBY).
PerformanceNBY-33.79%NVO-11.01%
2025-06-04+0.00%2026-04-02
MetricNBYNVO
Company
NovaBay Pharmaceuticals Inc.
Novo Nordisk A/S
Price
$1.95+21.50%
$42.01-2.10%
Market cap
$13.1M
$187.53B
1M return
+32.65%
-5.38%
1Y return
-33.79%
-41.69%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
AMEX
NYSE
IPO
2007
News (4w)
0
11
Recent ratings
0
25
NBY

NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market. It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and CelleRx Clinical Reset through online sales channels. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Latest NBY

Latest NVO